Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: A meta-analysis

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 3, 2011, Pages 287-291

  Lee, Ju Han ^a   Choi, Jung Woo ^a   Kim, Young Sik ^a  

^a Korea University   (South Korea)

Author keywords

Colorectal cancer; Meta analysis; Survival; TIMP 1

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PUBLICATION BIAS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 80053542909     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
3. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298: 29-32.
4. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304.
5. Kim YS, Seo DW, Kong SK, et al. TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation. Cancer Lett 2008; 269: 37-45.
6. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998; 92: 1342-1349.
7. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/ phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003; 278: 40364-40372.
8. Liu XW, Taube ME, Jung KK, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898-906.
9. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003; 312: 1196-1201.
10. Birgisson H, Nielsen HJ, Christensen IJ, Glimelius B, Brünner N. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: A prospective validation study. Eur J Cancer 2010; 46: 3323-3331.
11. Holten-Andersen M, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. A validation study. Eur J Cancer 2004; 40: 64-72.
12. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292-4299.
13. Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology 2007; 72: 205-208.
14. Ishida H, Murata N, Hayashi Y, Tada M, Hashimoto D. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today 2003; 33: 885-892.
15. Giaginis C, Nikiteas N, Margeli A, et al. Serum tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) levels in colorectal cancer patients: associations with clinicopathological variables and patient survival. Int J Biol Markers 2009; 24: 245-252.
16. Yukawa N, Yoshikawa T, Akaike M, et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer. Anticancer Res 2004; 24: 2101-2105.
17. Jensen SA, Vainer B, Bartels A, Brünner N, Sørensen JB. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells - associations with histopathology and patients outcome. Eur J Cancer 2010; 46: 3233-3242.
18. Unsal D, Akyurek N, Uner A, et al. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy. Am J Clin Oncol 2008; 31: 55-63.
19. Roca F, Mauro LV, Morandi A, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol 2006; 93: 151-160.
20. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-359.
21. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
22. Lee JH, Lee ES, Kim YS. Clinicopathologic signifcance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110: 38-46.
23. Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 2009; 24: 354-365.
24. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198.
25. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
26. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004; 10: 2289-2298.
27. Lipton A, Leitzel K, Chaudri-Ross HA, et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol 2008; 26: 2653-2658.
28. Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 2008; 7: 424-430.
29. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 2005; 103: 1676-1684.